Metformin before and during pregnancy and lactation in polycystic ovary syndrome

Expert Opinion on Drug Safety

Volumn 6, Issue 2, 2007, Pages 191-198

  Glueck, Charles J ^a   Wang, Ping ^a  

^a JEWISH HOSPITAL   (United States)

Author keywords

Infant growth; Infant motor social development; Lactation; Metformin; Polycystic ovary syndrome

Indexed keywords

GLUCOSE; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE;

ARTICLE; ARTIFICIAL MILK; BREAST FEEDING; BREAST MILK; CHILD GROWTH; CLINICAL TRIAL; CONCEPTION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MILK LEVEL; DRUG SAFETY; FIRST TRIMESTER PREGNANCY; GLUCOSE BLOOD LEVEL; GROWTH RETARDATION; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; LACTATION; MOTOR DEVELOPMENT; NONHUMAN; OVARY POLYCYSTIC DISEASE; PERINATAL DRUG EXPOSURE; PREGNANCY; PREGNANCY DIABETES MELLITUS; RISK BENEFIT ANALYSIS; SOCIAL EVOLUTION; SPONTANEOUS ABORTION; TERATOGENICITY; UNSPECIFIED SIDE EFFECT;

FEMALE; HUMANS; INFANT; LACTATION; METFORMIN; POLYCYSTIC OVARY SYNDROME; PREGNANCY; TIME FACTORS;

EID: 33847722632     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.6.2.191     Document Type: Article

References (68)

1. KNOCHENHAUER ES, KEY TJ, KAHSAR-MILLER M, WAGGONER W, BOOTS LR, AZZIZ R: Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin. Endocrinol. Metab. (1998) 83:3078-3082.
2. FRANKS S: Polycystic ovary syndrome. N. Engl. J. Med. (1995) 333:853-861.
3. ROTTERDAM ESHRE/ASRM-SPONSORED PCOS CONSENSUS WORKSHOP GROUP: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. (2004) 81:19-25.
4. EHRMANN DA: Polycystic ovary syndrome. N. Engl. J. Med. (2005) 352:1223-1236.
5. EHRMANN DA, STURIS J, BYRNE MM, KARRISON T, ROSENFIELD RL, POLONSKY KS: Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J. Clin. Invest. (1995) 96:520-527.
6. VELAZQUEZ EM, MENDOZA S, HAMER T, SOSA F, GLUECK CJ: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism (1994) 43:647-654.
7. VELAZQUEZ EM, MENDOZA SG, WANG P, GLUECK CJ: Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism (1997) 46:454-457.
8. GLUECK CJ, WANG P, FONTAINE R, TRACY T, SIEVE-SMITH L: Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism (1999) 48:511-519.
9. HARBORNE LR, SATTAR N, NORMAN JE, FLEMING R: Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J. Clin. Endocrinol. Metab. (2005) 90:4593-4598.
10. BAILLARGEON JP, JAKUBOWICZ DJ, IUOMO MJ, JAKUBOWICZ S, NESTLER JE: Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Obstet. Gynecol. Surv. (2005) 60:178-179.
11. HOMBURG R: Polycystic ovary syndrome in adolescence. New insights in pathophysiology and treatment. Endocr. Dev. (2005) 8:137-149.
12. KUMARI AS, HAQ A, JAYASUNDARAM R, ABDEL-WARETH LO, AL HAIJA SA, ALVARES M: Metformin monotherapy in lean women with polycystic ovary syndrome. Reprod. Biomed. Online (2005) 10:100-104.
13. PALOMBA S, ORIO F Jr, FALBO A et al.: Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (2005) 90:4068-4074.
14. NESTLER JE, JAKUBOWICZ DJ, EVANS WS, PASQUALI R: Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N. Engl. J. Med. (1998) 338:1876-1880.
15. LIU JH, BILL AH: Expanding applications for metformin in polycystic ovarian syndrome. J. Pediatr. (2006) 148:573-574.
16. CHECA MA, REQUENA A, SALVADOR C et al.: Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome. Hum. Reprod. Update (2005) 11:375-390.
17. GARDINER SJ, BEGG EJ, KIRKPATRICK CM, BUCKHAM RB: Metformin therapy and diabetes in pregnancy. Med. J. Aust. (2004) 181:174-175.
18. GILBERT C, VALOIS M, KOREN G: Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil. Steril. (2006) 86:658-663.
19. GLUECK CJ, PHILLIPS H, CAMERON D, SIEVE-SMITH L, WANG P: Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil. Steril. (2001) 75:46-52.
20. GLUECK CJ, WANG R KOBAYASHI S, PHILLIPS H, SIEVE-SMITH L: Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil. Steril. (2002) 77:520-525.
21. GLUECK CJ, WANG P, GOLDENBERG N, SIEVE-SMITH L: Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum. Reprod. (2002) 17:2858-2864.
22. GLUECK CJ, BORNOVALI S, PRANIKOFF J, GOLDENBERG N, DHARASHIVKAR S, WANG P: Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome. Diabet. Med. (2004) 21:829-836.
23. GLUECK CJ, GOLDENBERG N, WANG P, LOFTSPRING M, SHERMAN A: Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. Hum. Reprod (2004) 19:510-521.
24. GLUECK CJ, SALEHI M, SIEVE L, WANG P: Growth, motor, and social development in breast- and formula-fed infants of metformin-treated women with polycystic ovary syndrome. J. Pediatr. (2006) 148:628-632.
25. COETZEE EJ, JACKSON WP: Diabetes newly diagnosed during pregnancy: a 4-year study at Groote Schuur Hospital. S. Afr. Med. J. (1979) 56:467-475.
26. COETZEE EJ, JACKSON WP: Pregnancy in established non-insulin-dependent diabetics. A five-and-a-half year study at Groote Schuur Hospital. S. Afr. Med. J. (1980) 58:795-802.
27. LEGRO RS, MYERS ER, BARNHART HX et al.: The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects. Fertil. Steril. (2006) 86:914-933.
28. THATCHER SS, JACKSON EM: Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin. Fertil. Steril. (2006) 85:1002-1009.
29. GLUECK CJ, SIEVE L, ZHU B, WANG P: Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome. Metabolism (2006) 55:345-352.
30. KHATTAB S, MOHSEN IA, FOUTOUH IA, RAMADAN A, MOAZ M, AL-INANY H: Metformin reduces abortion in pregnant women with polycystic ovary syndrome. Gynecol. Endocrinol. (2006) 22:680-684.
31. GLUECK CJ, GOLDENBERG N, STREICHER P, WANG P: The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin. Expert Opin. Pharmacother. (2002) 3:1557-1568.
32. GLUECK CJ, GOLDENBERG N, STREICHER P, WANG P: Metformin and gestational diabetes. Curr. Diab. Rep. (2003) 3:303-312.
33. GLUECK CJ, WANG P, GOLDENBERG N, SIEVE L: Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin. Clin. Appl. Thromb. Hemost. (2004) 10:323-334.
34. JAKUBOWICZ DJ, IUORNO MJ, JAKUBOWICZ S, ROBERTS KA, NESTLER JE: Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (2002) 87:524-529.
35. VANKY E, SALVESEN KA, HEIMSTAD R, FOUGNER KJ, ROMUNDSTAD P, CARLSEN SM: Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum. Reprod. (2004) 19:1734-1740.
36. GLUECK CJ, GOLDENBERG N, PRANIKOFF J, LOFTSPRING M, SIEVE L, WANG P: Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum. Reprod. (2004) 19:1323-1330.
37. HAGUE WM DP, OLIVER J, ROWAN J: Contraindications to use of metformin. metformin may be useful in gestational diabetes. Br. Med. J. (2003) 326:762.
38. BAILLARGEON JP, IUORNO MJ, NESTLER JE: Insulin sensitizers for polycystic ovary syndrome. Clin. Obstet. Gynecol. (2003) 46:325-340.
39. HALE TW, KRISTENSEN JH, HACKETT LP, KOHAN R, ILETT KF: Transfer of metformin into human milk. Diabetologia (2002) 45:1509-1514.
40. BRIGGS GG, AMBROSE PJ, NAGEOTTE MP, PADILLA G, WAN S: Excretion of metformin into breast milk and the effect on nursing infants. Obstet. Gynecol. (2005) 105:1437-1441.
41. GARDINER SJ, KIRKPATRICK CM, BEGG EJ, ZHANG M, MOORE MP, SAVILLE DJ: Transfer of metformin into human milk. Clin. Pharmacol. Ther. (2003) 73:71-77.
42. DEROSA G, FRANZETTI I, GADALETA G, CICCARELLI L, FOGARI R: Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin. Diabetes Nutr. Metab. (2004) 17:143-150.
43. MARASCO L, MARMET C, SHELL E: Polycystic ovary syndrome: a connection to insufficient milk supply? J. Hum. Lact. (2000) 16:143-148.
44. PEDIATRICS AAO: Your child's growth: developmental milestones. American Academy of Pediatrics Pamphlet (1993): 1-3.
45. HALE T, KRISTENSEN J, HACKETT L, KOHAN R, ILETT K: Transfer of metformin into human milk. Adv. Exp. Med. Biol. (2004) 554:435-436.
46. GLUECK CJ, PAPANNA R, WANG P, GOLDENBERG N, SIEVE-SMITH L: Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism (2003) 52:908-915.
47. VANKY E, SALVESEN KA, HJORTH-HANSEN H, BJERVE K, CARLSEN SM: Beneficial effect of metformin on pregnancy outcome in women with polycystic ovary syndrome is not associated with major changes in C-reactive protein levels or indices of coagulation. Fertil. Steril. (2006) 85:770-774.
48. MIRRETT PL, BAILEY DB Jr, ROBERTS JE, HATTON DD: Developmental screening and detection of developmental delays in infants and toddlers with fragile X syndrome. J. Dev. Behav. Pediatr. (2004) 25:21-27.
49. NEIMAN GS, SAVAGE HE: Development of infants and toddlers with clefts from birth to three years of age. Cleft Palate Craniofac. J. (1997) 34:218-225.
50. WALKER D, GUGENHEIM S, DOWNS MP, NORTHERN JL: Early Language Milestone Scale and language screening of young children. Pediatrics (1989) 83:284-288.
51. BAILLARGEON JP, JAKUBOWICZ DJ, IUORNO MJ, JAKUBOWICZ S, NESTLER JE: Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil. Steril. (2004) 82:893-902.
52. DIAMANTI-KANDARAKIS E, ALEXANDRAKI K, PIPERI C et al.: Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur. J. Clin. Invest. (2006) 36:691-697.
53. ESSAH PA, NESTLER JE: Metabolic syndrome in women with polycystic ovary syndrome. Fertil. Steril. (2006) 86(Suppl. 1):S18-S19.
54. GLUECK CJ, AREGAWI D, WINIARSKA M et al.: Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. J. Pediatr. Endocrinol. Metab. (2006) 19:831-842.
55. GLUECK CJ, MORRISON JA, FRIEDMAN LA, GOLDENBERG N, STROOP DM, WANG P: Obesity, free testosterone, and cardiovascular risk factors in adolescents with polycystic ovary syndrome and regularly cycling adolescents. Metabolism (2006) 55:508-514.
56. ORTEGA-GONZALEZ C, LUNA S, HERNANDEZ L et al.: Responses of serum androgen and insulin resistance m metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (2005) 90:1360-1365.
57. BELLI SH, GRAFFIGNA MN, ONETO A, OTERO P, SCHURMAN L, LEVALLE OA: Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil. Steril. (2004) 81:624-629.
58. CATALDO NA, ABBASI F, MCLAUGHLIN TL et al.: Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome. Hum. Reprod. (2006) 21:109-120.
59. CHAN LY, LAU TK, FUNG TM, CHOW KM: Re: Effects of rosiglitazone on hormonal profile and ovulatory function in Chinese women with polycystic ovary syndrome. Aust. NZ. J. Obstet. Gynaecol. (2006) 46:170-171.
60. DERELI D, DERELI T, BAYRAKTAR F, OZGEN AG, YILMAZ C: Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr. J. (2005) 52:299-308.
61. GHAZEERI G, KUTTEH WH, BRYER-ASH M, HAAS D, KE RW: Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil. Steril. (2003) 79:562-566.
62. BRETTENTHALER N, DE GEYTER C, HUBER PR, KELLER U: Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (2004) 89:3835-3840.
63. ELKIND-HIRSCH KE: Thiazolidinediones for the therapeutic management of polycystic ovary syndrome: impact on metabolic and reproductive abnormalities. Treat. Endocrinol. (2006) 5:171-187.
64. GARMES HM, TAMBASCIA MA, ZANTUT-WITTMANN DE: Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome. Gynecol. Endocrinol. (2005) 21:317-323.
65. YARIS F, YARIS E, KADIOGLU M, ULKU C, KESIM M, KALYONCU NI: Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman. Reprod. Toxicol. (2004) 18:619-621.
66. KALYONCU NI, YARIS F, ULKU C et al.: A case of rosiglitazone exposure in the second trimester of pregnancy. Reprod. Toxicol. (2005) 19:563-564.
67. SCIALLI AR, BUELKE-SAM JL, CHAMBERS CD et al.: Communicating risks during pregnancy: a workshop on the use of data from animal developmental toxicity studies in pregnancy labels for drugs. Birth Defects Res. A Clin. Mol. Teratol. (2004) 70:7-12.
68. KAUFMAN RH, ABBOTT JP, WALL JA: The endometrium before and after wedge resection of the ovaries in the Stein-Leventhal syndrome. Am. J. Obstet. Gynecol. (1959) 77:1271-1285.